ImmunoScape: Dan MacLeod, Katja Fink, Andreas Wilm

ImmunoScape has added Dan MacLeod as VP of discovery, Katja Fink as senior director of hit discovery, and Andreas Wilm as director of computational biology.

MacLeod will spearhead the firm's push into drug discovery. He brings over 15 years of experience in immunology, oncology, cancer, immunotherapy, and virology. He comes to ImmunoScape from Precision Biosciences, where he led research on gene-edited chimeric antigen receptor T cell therapies. He has also held research roles at GlaxoSmithKline and the Scripps Research Institute. He holds a doctorate in molecular pathology and biomedical sciences from UC-San Diego.

Fink brings 20 years of experience in basic and applied immunology research. Previously, she was director of antibody research at Humabs BioMed in Switzerland. She also established a research group at Singapore's A*STAR. She holds a master's degree in biochemistry from the University of Zurich and a doctorate in immunology from ETH Zurich.

Wilm comes to the firm from Microsoft, where he was a data and artificial intelligence expert on that company's worldwide public sector team. He also led the bioinformatics core at the Genome Institute of Singapore. He holds a doctorate in biology from the University of Dusseldorf.